335 related articles for article (PubMed ID: 23052407)
21. Pharmacokinetics of Bedrocan®, a cannabis oil extract, in fasting and fed dogs: An explorative study.
Łebkowska-Wieruszewska B; Stefanelli F; Chericoni S; Owen H; Poapolathep A; Lisowski A; Giorgi M
Res Vet Sci; 2019 Apr; 123():26-28. PubMed ID: 30580232
[TBL] [Abstract][Full Text] [Related]
22. Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers.
Martin-Santos R; Crippa JA; Batalla A; Bhattacharyya S; Atakan Z; Borgwardt S; Allen P; Seal M; Langohr K; Farré M; Zuardi AW; McGuire PK
Curr Pharm Des; 2012; 18(32):4966-79. PubMed ID: 22716148
[TBL] [Abstract][Full Text] [Related]
23. A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine.
Kinzler ER; Pantaleon C; Iverson M; Aigner S
Adv Ther; 2019 Sep; 36(9):2394-2401. PubMed ID: 31278694
[TBL] [Abstract][Full Text] [Related]
24. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
Rog DJ; Nurmikko TJ; Young CA
Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
[TBL] [Abstract][Full Text] [Related]
25. A multicentre, open-label, follow-on study to assess the long-term maintenance of effect, tolerance and safety of THC/CBD oromucosal spray in the management of neuropathic pain.
Hoggart B; Ratcliffe S; Ehler E; Simpson KH; Hovorka J; Lejčko J; Taylor L; Lauder H; Serpell M
J Neurol; 2015 Jan; 262(1):27-40. PubMed ID: 25270679
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of cannabichromene in a medical cannabis product also containing cannabidiol and Δ
Peters EN; MacNair L; Mosesova I; Christians U; Sempio C; Klawitter J; Land MH; Ware MA; Turcotte C; Bonn-Miller MO
Eur J Clin Pharmacol; 2022 Feb; 78(2):259-265. PubMed ID: 34664109
[TBL] [Abstract][Full Text] [Related]
27. A Novel Self-Emulsifying Drug Delivery System (SEDDS) Based on VESIsorb
Knaub K; Sartorius T; Dharsono T; Wacker R; Wilhelm M; Schön C
Molecules; 2019 Aug; 24(16):. PubMed ID: 31426272
[TBL] [Abstract][Full Text] [Related]
28. A Randomized, Triple-Blind, Comparator-Controlled Parallel Study Investigating the Pharmacokinetics of Cannabidiol and Tetrahydrocannabinol in a Novel Delivery System, Solutech, in Association with Cannabis Use History.
Berl V; Hurd YL; Lipshutz BH; Roggen M; Mathur EJ; Evans M
Cannabis Cannabinoid Res; 2022 Dec; 7(6):777-789. PubMed ID: 35787693
[No Abstract] [Full Text] [Related]
29. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
30. A Phase 1, Randomised, Placebo-Controlled, Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Cannabidiol in Fed Healthy Volunteers.
Perkins D; Butler J; Ong K; Nguyen TH; Cox S; Francis B; Mcintosh M; Lilley B
Eur J Drug Metab Pharmacokinet; 2020 Oct; 45(5):575-586. PubMed ID: 32409982
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic Variability of Oral Cannabidiol and Its Major Metabolites after Short-Term High-Dose Exposure in Healthy Subjects.
Zhang Q; Melchert PW; Markowitz JS
Med Cannabis Cannabinoids; 2024; 7(1):1-9. PubMed ID: 38292071
[TBL] [Abstract][Full Text] [Related]
32. Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice.
Vermersch P; Trojano M
Eur Neurol; 2016; 76(5-6):216-226. PubMed ID: 27732980
[TBL] [Abstract][Full Text] [Related]
33. Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from postapproval pragmatic studies.
Patti F
Neurodegener Dis Manag; 2019 Apr; 9(2s):3-7. PubMed ID: 30657027
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic and behavioural profile of THC, CBD, and THC+CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC.
Hložek T; Uttl L; Kadeřábek L; Balíková M; Lhotková E; Horsley RR; Nováková P; Šíchová K; Štefková K; Tylš F; Kuchař M; Páleníček T
Eur Neuropsychopharmacol; 2017 Dec; 27(12):1223-1237. PubMed ID: 29129557
[TBL] [Abstract][Full Text] [Related]
35. Urinary Pharmacokinetic Profile of Cannabidiol (CBD), Δ9-Tetrahydrocannabinol (THC) and Their Metabolites following Oral and Vaporized CBD and Vaporized CBD-Dominant Cannabis Administration.
Sholler DJ; Spindle TR; Cone EJ; Goffi E; Kuntz D; Mitchell JM; Winecker RE; Bigelow GE; Flegel RR; Vandrey R
J Anal Toxicol; 2022 May; 46(5):494-503. PubMed ID: 34089060
[TBL] [Abstract][Full Text] [Related]
36. Δ9-Tetrahydrocannabinol and Cannabidiol Time Courses in the Sera of "Light Cannabis" Smokers: Discriminating Light Cannabis Use from Illegal and Medical Cannabis Use.
Pichini S; Mannocchi G; Berretta P; Zaami S; Pirani F; Pacifici R; Busardò FP
Ther Drug Monit; 2020 Feb; 42(1):151-156. PubMed ID: 31389860
[TBL] [Abstract][Full Text] [Related]
37. THC and CBD concentrations in blood, oral fluid and urine following a single and repeated administration of "light cannabis".
Pacifici R; Pichini S; Pellegrini M; Rotolo MC; Giorgetti R; Tagliabracci A; Busardò FP; Huestis MA
Clin Chem Lab Med; 2020 Apr; 58(5):682-689. PubMed ID: 30956228
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetic Profile of ∆9-Tetrahydrocannabinol, Cannabidiol and Metabolites in Blood following Vaporization and Oral Ingestion of Cannabidiol Products.
Bergeria CL; Spindle TR; Cone EJ; Sholler D; Goffi E; Mitchell JM; Winecker RE; Bigelow GE; Flegel R; Vandrey R
J Anal Toxicol; 2022 Jul; 46(6):583-591. PubMed ID: 35438179
[TBL] [Abstract][Full Text] [Related]
39. A Phase I Trial to Determine the Pharmacokinetics, Psychotropic Effects, and Safety Profile of a Novel Nanoparticle-Based Cannabinoid Spray for Oromucosal Delivery.
Lorenzl S; Gottwald F; Nistler A; Brehm L; Grötsch R; Haber G; Bremm C; Weck C; Trummer C; Brand W
Med Cannabis Cannabinoids; 2022; 5(1):9-19. PubMed ID: 35224436
[TBL] [Abstract][Full Text] [Related]
40. A validated method for the simultaneous quantification of cannabidiol, Δ
Kevin RC; Vogel R; Doohan P; Berger M; Amminger GP; McGregor IS
Drug Test Anal; 2021 Mar; 13(3):614-627. PubMed ID: 33095968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
